8-K: Leidos Reports Strong Q3 2024 Results, Raises Full-Year Guidance

Leidos announced strong third-quarter results for 2024, with a 7% year-over-year revenue increase and raised its full-year guidance.

Summary

• Leidos reported a 7% increase in revenue year-over-year, reaching $4.19 billion for the third quarter of 2024.
• Net income for the quarter was $362 million, or $2.68 per diluted share, a significant improvement compared to a net loss in the same quarter last year.
• Adjusted EBITDA reached $596 million, with a record margin of 14.2%, up from 11.5% in the third quarter of 2023.
• Non-GAAP diluted earnings per share were $2.93, a 44% increase year-over-year.
• The company generated $656 million in cash flow from operations and $633 million in free cash flow.
• Net bookings for the quarter totaled $8.1 billion, resulting in a book-to-bill ratio of 1.9.
• Leidos is updating its fiscal year 2024 revenue guidance to $16.35 $16.45 billion, adjusted EBITDA margin to high-12%, and non-GAAP diluted EPS to $9.80 $10.00.
• The company's backlog at the end of the quarter was $40.6 billion, with $9.1 billion funded.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong financial results, increased guidance, and positive management commentary. The company's performance significantly exceeded expectations, indicating a strong outlook.

Positives

• Leidos experienced strong revenue growth across all customer segments, particularly in managed health services.
• The company achieved record margins for net income and adjusted EBITDA.
• There was substantial growth in earnings and strong cash flow generation.
• Leidos had robust bookings, indicating strong future revenue potential.
• The company increased its quarterly dividend by 5.3% to $0.40 per share.
• The company is well-positioned to deliver robust and sustainable returns due to a healthy balance sheet and improving business development performance.
• The company has a strong backlog of $40.6 billion.

Negatives

• Comparisons to the prior year are skewed due to a $699 million pre-tax, non-cash impairment and restructuring charge in Q3 2023.
• The company has $4.7 billion of debt as of September 27, 2024.

Risks

• The company is subject to risks related to U.S. government defense and non-defense budgets, including potential budget reductions and delays.
• There are uncertainties in tax due to new tax legislation or other regulatory developments.
• The company faces risks related to delays in the U.S. government contract procurement process.
• Leidos is exposed to cybersecurity, data security, and other security threats.
• The company's ability to accurately estimate costs on fixed-price contracts is a risk.
• The company is subject to risks related to its international business and compliance with anti-corruption laws.
• The company's ability to grow its commercial health and infrastructure businesses could be negatively affected by budgetary constraints.

Future Outlook

Leidos is updating its fiscal year 2024 guidance, projecting revenues of $16.35 $16.45 billion, an adjusted EBITDA margin of high-12%, and non-GAAP diluted EPS of $9.80 $10.00. The company also expects approximately $1.35 billion in cash flows from operating activities.

Management Comments

• Continued improvement in operating performance across all segments drove excellent revenue growth, record margins for net income and adjusted EBITDA, substantial earnings growth, strong cash flow, and robust bookings, said Leidos Chief Executive Officer Tom Bell.
• These results demonstrate clearly how our collaborative and innovative workforce is focused on consistent execution for our customers and shareholders.
• With a healthy balance sheet, improving business development performance, and emerging 'North Star' strategy, Leidos is well positioned to deliver robust and sustainable returns as we move forward.

Industry Context

Leidos' strong performance reflects a positive trend in the government contracting sector, particularly in areas like managed health services and defense technology. The company's focus on innovation and collaboration aligns with the industry's increasing demand for advanced technology solutions.

Comparison to Industry Standards

• Leidos' 7% revenue growth is solid compared to peers in the government contracting space, such as General Dynamics (GD) and Lockheed Martin (LMT), which have seen varying growth rates in recent quarters.
• The adjusted EBITDA margin of 14.2% is competitive, potentially exceeding the average margins of some of its peers, such as Booz Allen Hamilton (BAH), which often operate in the 10-12% range.
• The book-to-bill ratio of 1.9 indicates strong demand for Leidos' services, which is a positive sign compared to companies with lower ratios, such as CACI International (CACI).
• The company's free cash flow generation of $633 million is a strong indicator of financial health, comparable to other large government contractors with similar cash flow profiles.
• The increase in dividend by 5.3% is a positive sign for investors, and is in line with other mature companies in the sector.

Stakeholder Impact

• Shareholders will benefit from increased earnings, a higher dividend, and a positive outlook.
• Employees will benefit from the company's strong performance and focus on innovation.
• Customers will benefit from Leidos' commitment to consistent execution and delivery of high-quality solutions.
• Suppliers and creditors will benefit from the company's strong financial position and cash flow generation.

Next Steps

• Leidos will continue to execute its 'North Star' strategy.
• The company will focus on delivering robust and sustainable returns.
• Leidos will continue to monitor and respond to developments in government budgets and procurement processes.

Key Dates

Keywords

Leidos, Financial Results, Third Quarter, Revenue, EBITDA, Earnings Per Share, Bookings, Guidance, Defense, Health, Technology, Government Contracts